Supraspinatus TendinitisNCT07316712
Effect of TECAR (Transfer of Energy Capacitive and Resistive) Therapy on Chronic Supraspinatus Tendinitis
A study testing Conventional treatment and TECAR (Transfer of Energy Capacitive and Resistive) Therapy in people with Supraspinatus Tendinitis, run by Cairo University at 1 site in Egypt.
Trial summary
This study aims to investigate the effect of TECAR therapy on pain, shoulder range of motion, functional disability, and handgrip strength in patients with grade II supraspinatus tendinitis. Read more about this study
- Who is it for?
- Ages 30 to 55 years
- Conditions the study is for
- Supraspinatus Tendinitis
- What is being tested?
- Conventional treatment and TECAR (Transfer of Energy Capacitive and Resistive) Therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 46 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Dec 2025to 28 Feb 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Supraspinatus Tendinitis grade II based on Neer's classification, confirmed by special tests, signs, and symptoms of grade I and II Supraspinatus Tendinitis for the past month, and taking non-steroidal anti-inflammatory drugs as suggested by the physician.
- All patients will have a body mass index between 18.5 and 29.9 kg/m².
Who cannot join
- Other grades of Supraspinatus Tendinitis.
- Any past shoulder surgical interventions.
- Instability of the shoulder joint due to other reasons, Acromioclavicular Joint Arthritis.
- Non-cooperative subjects.
- Diabetes
- Pregnant or lactating women.
Show all 11Show fewer
- Serious neuromuscular or cardiovascular diseases.
- Systemic illness and severe COVID-19 cases will be excluded from this study.
- Pacemakers
- Heat Sensitivity
- Metal Implants
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hend Hamdy Mohamed Ahmed, PhD contact
Egypt1 site
CAN Center outpatient clinic
Cairo
Mohamed Gamal Ibrahem Alghamry, B.Sc, +20 114 448 1731, Mohamed.gamal.2651997@gmail.com
About this study
This study aims to investigate the effect of TECAR therapy on pain, shoulder range of motion, functional disability, and handgrip strength in patients with grade II supraspinatus tendinitis.
Read the detailed description
Tendinopathy occurs when pain arises in a tendon near its origin or insertion due to repetitive activities and reduced functional levels. It happens when the tendon does not properly heal. Thirty percent of tendinopathies related to musculoskeletal conditions are associated with shoulder pain, and supraspinatus tendinitis is the third most prevalent problem.
The supraspinatus tendon, part of the rotator cuff of the shoulder joint, is particularly affected. Aging is also a common factor leading to supraspinatus tendon injuries. The primary function of the supraspinatus muscle is shoulder abduction, particularly during movements that elevate the arm overhead. During these motions, the supraspinatus tendon repeatedly passes beneath the acromion process of the scapula, which can result in impingement and subsequent inflammation. An unexpected force or trauma may cause a partial or complete tendon rupture if this condition progresses.
Transfer of Energy Capacitive and Resistive (TECAR) offers a unique variety of treatments for chronic and acute pathologies, with contraindications such as pregnancy, pacemakers, and sensitivity to high temperatures. It should be noted that this new technology is a valuable tool in treating various pathologies, particularly when compared with other therapies in terms of the presence and/or absence of specific positive effects. TECAR also has distinct characteristics that are effective even when other treatments fail. This therapy balances the therapist's manual skills and the specialized energy that this technology offers, resulting in increasingly satisfactory outcomes for therapists and patients.
- Conditions
- Supraspinatus Tendinitis
- Being tested
- Conventional treatment, TECAR (Transfer of Energy Capacitive and Resistive) Therapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Conventional treatmentOther
All patients in both groups will receive conventional treatment, 3 sessions per week for 3 weeks. The conventional methods for treating supraspinatus tendinitis include shoulder swings, painless range of motion (ROM) exercises, shoulder joint active-assisted exercises, resistance exercises to improve muscle strength, and pain-reducing physiotherapy modalities like ultrasound.
TECAR (Transfer of Energy Capacitive and Resistive) TherapyDevice
Patients in the experimental group only will receive TECAR therapy, 3 sessions per week for 3 weeks. The treatment will start with an automatic capacitive energy transfer for 10 minutes. Next, the capacitive plaque will be replaced by the resistive electrode, and the neutral electrode will be fixed
| Study group | Role | What they receive |
|---|---|---|
| Conventional treatment + TECAR therapy | Experimental | The experimental group will receive conventional physiotherapy sessions as the active comparator group, in addition to TECAR therapy at the end of each session. Sessions will be received for three weeks (nine sessions, three times per week). Receives: Other: Conventional treatment; Device: TECAR (Transfer of Energy Capacitive and Resistive) Therapy |
| Conventional treatment | Active comparator | The active comparator group will receive conventional physiotherapy sessions for three weeks (nine sessions, three times per week). Receives: Other: Conventional treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of Pain Intensity of Shoulder Joint by Numerical Rating Scale (NRS)
The Numerical Rating Scale (NRS) will evaluate shoulder pain when using the NRS. Patients will be asked to rate their pain on a scale from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain possible.
Measured: 3 weeks
Secondary outcomes (4)
Assessment of Shoulder abduction range of motion
A digital goniometer will be used to assess shoulder joint abduction range of motion in patients with chronic supraspinatus tendinitis before and after the treatment sessions. Measurements will be taken with the patient in the supine position. The fulcrum of the goniometer will be centered at the anterior aspect of the acromion process, the stationary arm will be aligned parallel to the midline of the torso, and the moving arm will be aligned with the midline of the humerus, pointing toward the medial epicondyle of the elbow.
Measured: 3 weeks
Assessment of Shoulder External Rotation range of motion
Shoulder joint external rotation range of motion will also be assessed using a digital goniometer before and after the treatment sessions in patients with chronic supraspinatus tendinitis. The patient will be positioned supine during measurement. The fulcrum of the goniometer will be centered over the olecranon process of the elbow, the stationary arm will be aligned perpendicular to the floor, and the moving arm will be aligned with the ulna, pointing toward the ulnar styloid process.
Measured: 3 weeks
Assessment of Handgrip strength by handheld dynamometer
A JAMAR hand dynamometer (Sammons Preston Inc, Bolingbrook, IL, USA) will be used to measure grip strength in kilograms. The Jamar is small and portable but relatively heavy at 1.5 lb. The dial reads force in both kilograms and pounds, with markings at intervals of 2 kg or 5 lb, allowing assessment to the nearest 1 kg or 2.5 lb. The reading error is reported to be greater at lower loadings. This method has high test-retest reliability. Also, it has both inter and intra-rater reliability.
Measured: 3 weeks
Assessment of Functional disability by QuickDASH Scale (Arabic Version)
The QuickDASH includes 30 items, with six items about symptoms (3 about pain, 1 for tingling/numbness, 1 for weakness, 1 for stiffness) and 24 about function (21 about physical function, 3 about social/role function). For each question, the subject rated the performance in the last week on a 5-point scale (1 = no difficulty to perform or no impact; 5 = unable to do or high impact). The raw score is the sum of all answers (maximum score: 150; minimum score: 30). The raw score is transformed into a zero to 100 scale (= total DASH). Zero is no disability and 100 maximum disability.
Measured: 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2026
- Study start30 Dec 2025 (estimated)
- Primary completion15 Feb 2026 (estimated)
- Study completion28 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Supraspinatus TendinitisStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 46 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Gamal Ibrahem Alghamry, Cairo University
- Investigators
- Hanaa Kenawy Atta, PhD, Study chair, Assistant Professor, Cairo UniversityHend Hamdy Mohamed Ahmed, PhD, Study director, Lecturer, Cairo university
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07316712
- Sponsor's protocol ID
- P.T.REC/012/005900
- Status last verified
- Dec 2025
- First submitted
- 19 Dec 2025
- Last updated
- 5 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of TECAR (Transfer of Energy Capacitive and Resistive) Therapy on Chronic Supraspinatus Tendinitis
- ClinicalTrials.gov ID
- NCT07316712
- Acronym / sponsor ID
- P.T.REC/012/005900
- Conditions
- Supraspinatus Tendinitis
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 46 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 30 Dec 2025 (estimated)
- Primary completion
- 15 Feb 2026 (estimated)
- Study completion
- 28 Feb 2026 (estimated)
- First posted
- 5 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate the effect of TECAR therapy on pain, shoulder range of motion, functional disability, and handgrip strength in patients with grade II supraspinatus tendinitis.
Detailed description
Tendinopathy occurs when pain arises in a tendon near its origin or insertion due to repetitive activities and reduced functional levels. It happens when the tendon does not properly heal. Thirty percent of tendinopathies related to musculoskeletal conditions are associated with shoulder pain, and supraspinatus tendinitis is the third most prevalent problem.
The supraspinatus tendon, part of the rotator cuff of the shoulder joint, is particularly affected. Aging is also a common factor leading to supraspinatus tendon injuries. The primary function of the supraspinatus muscle is shoulder abduction, particularly during movements that elevate the arm overhead. During these motions, the supraspinatus tendon repeatedly passes beneath the acromion process of the scapula, which can result in impingement and subsequent inflammation. An unexpected force or trauma may cause a partial or complete tendon rupture if this condition progresses.
Transfer of Energy Capacitive and Resistive (TECAR) offers a unique variety of treatments for chronic and acute pathologies, with contraindications such as pregnancy, pacemakers, and sensitivity to high temperatures. It should be noted that this new technology is a valuable tool in treating various pathologies, particularly when compared with other therapies in terms of the presence and/or absence of specific positive effects. TECAR also has distinct characteristics that are effective even when other treatments fail. This therapy balances the therapist's manual skills and the specialized energy that this technology offers, resulting in increasingly satisfactory outcomes for therapists and patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Conventional treatment + TECAR therapy | Experimental | Other: Conventional treatment, Device: TECAR (Transfer of Energy Capacitive and Resistive) TherapyThe experimental group will receive conventional physiotherapy sessions as the active comparator group, in addition to TECAR therapy at the end of each session. Sessions will be received for three weeks (nine sessions, three times per week). |
| Conventional treatment | Active comparator | Other: Conventional treatmentThe active comparator group will receive conventional physiotherapy sessions for three weeks (nine sessions, three times per week). |
Who may qualify
- Ages
- 30 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Supraspinatus Tendinitis grade II based on Neer's classification, confirmed by special tests, signs, and symptoms of grade I and II Supraspinatus Tendinitis for the past month, and taking non-steroidal anti-inflammatory drugs as suggested by the physician.
- All patients will have a body mass index between 18.5 and 29.9 kg/m².
Key exclusion criteria (11 listed)
- Other grades of Supraspinatus Tendinitis.
- Any past shoulder surgical interventions.
- Instability of the shoulder joint due to other reasons, Acromioclavicular Joint Arthritis.
- Non-cooperative subjects.
- Diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Conventional treatmentAll patients in both groups will receive conventional treatment, 3 sessions per week for 3 weeks. The conventional methods for treating supraspinatus tendinitis include shoulder swings, painless range of motion (ROM) exercises, shoulder joint active-assisted exercises, resistance exercises to improve muscle strength, and pain-reducing physiotherapy modalities like ultrasound. | Other | Conventional treatment, Conventional treatment + TECAR therapy |
| TECAR (Transfer of Energy Capacitive and Resistive) TherapyPatients in the experimental group only will receive TECAR therapy, 3 sessions per week for 3 weeks. The treatment will start with an automatic capacitive energy transfer for 10 minutes. Next, the capacitive plaque will be replaced by the resistive electrode, and the neutral electrode will be fixed | Device | Conventional treatment + TECAR therapy |
Primary outcome
Assessment of Pain Intensity of Shoulder Joint by Numerical Rating Scale (NRS)
Time frame: 3 weeks
The Numerical Rating Scale (NRS) will evaluate shoulder pain when using the NRS. Patients will be asked to rate their pain on a scale from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain possible.
4 secondary outcomes
Assessment of Shoulder abduction range of motion
Time frame: 3 weeks
Assessment of Shoulder External Rotation range of motion
Time frame: 3 weeks
Assessment of Handgrip strength by handheld dynamometer
Time frame: 3 weeks
Assessment of Functional disability by QuickDASH Scale (Arabic Version)
Time frame: 3 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2026.
Related trials for Supraspinatus Tendinitis
Recruiting
Effects of Cervicothoracic Mobilization in Patients With Supraspinatus Tendinitis
Rotator Cuff Tendonitis
Recruiting
HILT vs ESWT in Supraspinatus Tendinitis
Supraspinatus Tendinitis
Recruiting
Anatomical Evaluation of Supraspinatus Through Ultrasonography and Biomechanical Measurements Following Blood Flow Restriction Therapy and Eccentric Exercise in Patients of Supraspinatus Tendinitis.
Supraspinatus Tendinitis
Recruiting
Reverse Fly Exercise On Supraspinatus Tendinitis In Patients Receiving Aromatase Inhibitors Therapy After Mastectomy
Mastectomy, Aromatase Inhibitors Therapy
Active, not recruiting
Anatomical Evaluation of Supraspinatus Through Ultrasonography and Biomechanical Measurements Following Different Combinations of Physical Therapies in Patients of Supraspinatus Tendinitis
Supraspinatus Tendinitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hend Hamdy Mohamed Ahmed, PhD contact
Hanaa Kenawy Atta, PhD study chair
Assistant Professor, Cairo University
Hend Hamdy Mohamed Ahmed, PhD study director
Lecturer, Cairo university
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Conventional treatment and TECAR (Transfer of Energy Capacitive and Resistive) Therapy in people with Supraspinatus Tendinitis, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed Gamal Ibrahem Alghamry, B.Sc (+20 114 448 1731, Mohamed.gamal.2651997@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of Pain Intensity of Shoulder Joint by Numerical Rating Scale (NRS) (time frame: 3 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2026.